- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Alexion Pharmaceuticals Inc
Add to PortfolioALXN:US
92.4200 USD 0.6800 0.73%As of 20:10:00 ET on 05/25/2012.
Snapshot for Alexion Pharmaceuticals Inc (ALXN)
| Open: | 93.0400 | Day's Range: | 91.3800 - 93.3600 | Volume: | 2,832,049 | Bid: | 92.3900 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 93.1000 | 52wk Range: | 43.7800 - 95.0100 | 1-Yr Rtn: | +100.13% | Ask: | 92.4000 |
Key Statistics for ALXN
| Current P/E Ratio (ttm) | 95.2783 |
|---|---|
| Estimated P/E (12/2012) | 51.5449 |
| Earnings Per Share (USD) (ttm) | 0.9700 |
| Est. EPS (USD) (12/2012) | 1.7930 |
| Est. PEG Ratio | 1.3473 |
| Market Cap (M USD) | 17,275.52 |
| Shares Outstanding (M) | 186.92 |
| Enterprise Value (M USD) (ttm) | 17,271.13 |
| Enterprise Value/EBITDA (ttm) | 58.17 |
| Price/Book (mrq) | 14.2437 |
| Price/Sale (ttm) | 19.7588 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/20/2012 |
More ALXN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for ALXN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for ALXN
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
| Max E LinkChairman | Leonard BellCEO/Secy/Treasurer/Founder |
| Stephen P SquintoExec VP/Head:Research & Dev | Vikas SinhaSenior VP/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page